Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation

다국어 초록 (Multilingual Abstract)

Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and associated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with sequential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. However, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declining β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-implemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients worldwide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical implementation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evidence.

참고문헌 (Reference)

1 Halban PA, "β-Cell failure in type 2 diabetes : postulated mechanisms and prospects for prevention and treatment" 99 : 1983-1992, 2014

2 Avogaro A, "When metformin is not enough : pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy" 34 : e2981-, 2018

3 Phillips LS, "We can change the natural history of type 2 diabetes" 37 : 2668-2676, 2014

4 Bosi E, "Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus" 11 : 506-515, 2009

5 Matthews DR, "Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain : results from a 2-year study" 12 : 780-789, 2010

6 Mathieu C, "Vildagliptin : a new oral treatment for type 2 diabetes mellitus" 4 : 1349-1360, 2008

7 Rashid M, "Variability in the therapeutic response of metformin treatment in patients with type 2 diabetes mellitus" 35 : 71-76, 2019

8 Mosenzon O, "VERIFY the role of initial combination therapy in patients with type 2 diabetes" 394 : 1483-1485, 2019

9 Ma RC, "Type 2 diabetes in East Asians : similarities and differences with populations in Europe and the United States" 1281 : 64-91, 2013

10 Prattichizzo F, "Two drugs are better than one to start T2DM therapy" 16 : 15-16, 2020

11 Fu AZ, "Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy" 13 : 765-769, 2011

12 Fu AZ, "Treatment intensification for patients with type 2 diabetes and poor glycaemic control" 18 : 892-898, 2016

13 Strain WD, "Time to do more : addressing clinical inertia in the management of type 2 diabetes mellitus" 105 : 302-312, 2014

14 Chen L, "The worldwide epidemiol-ogy of type 2 diabetes mellitus : present and future perspectives" 8 : 228-236, 2011

15 Kahn SE, "The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes" 46 : 3-19, 2003

16 Stark Casagrande S, "The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010" 36 : 2271-2279, 2013

17 Brath H, "The physician’s choice: single pill or fixed-dose combination?" 2017

18 Rena G, "The mechanisms of action of metformin" 60 : 1577-1585, 2017

19 Tuomi T, "The many faces of diabetes : a disease with increasing heterogeneity" 383 : 1084-1094, 2014

20 Ahren B, "The islet enhancer vildagliptin : mechanisms of improved glucose metabolism" 159 : 8-14, 2008

21 Wu S, "The effects of incretinbased therapies on β-cell function and insulin resistance in type 2 diabetes : a systematic review and network meta-analysis combining 360 trials" 21 : 975-983, 2019

22 Heise T, "The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes" 16 : 1036-1039, 2014

23 Khazrai YM, "The addition of E(Empowerment and Economics)to the ABCD algorithm in diabetes care" 29 : 599-606, 2015

24 Thomas MC, "The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure" 61 : 2098-2107, 2018

25 Molugulu N, "Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor(SGLT-2)in treatment of type 2 diabetes mellitus" 132 : 157-168, 2017

26 Del Prato S, "Study to determine the durability of glycaemic control with early treatment with a vildagliptinmetformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial : a randomized doubleblind trial" 31 : 1178-1184, 2014

27 Kalra S, "Sodium glucose co-transporter-2(SGLT2)inhibitors : a review of their basic and clinical pharmacology" 5 : 355-366, 2014

28 Migoya EM, "Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations" 56 (56): A74-, 2007

29 Kramer CK, "Short-term intensive insulin therapy in type 2 diabetes mellitus : a systematic review and meta-analysis" 1 : 28-34, 2013

30 Brown JB, "Secondary failure of metformin monotherapy in clinical practice" 33 : 501-506, 2010

31 Zelniker TA, "SGLT2inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials" 393 : 31-39, 2019

32 Meier JJ, "Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes" 36 (36): S113-S119, 2013

33 RISE Consortium, "Restoring Insulin Secretion(RISE) : design of studies of β-cell preservation in prediabetes and early type 2diabetes across the life span" 37 : 780-788, 2014

34 Xu W, "Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study" 122 : 2554-2559, 2009

35 Giannarelli R, "Reducing insulin resistance with metformin : the evidence today" 29 (29): 6S28-6S35, 2003

36 Nathan DM, "Rationale and design of the glycemia reduction approaches in diabetes : a comparative effectiveness study(GRADE)" 36 : 2254-2261, 2013

37 Agency for Healthcare Research and Quality (AHRQ), "Quality and patient safety resources"

38 Uusitupa M, "Prevention of type 2diabetes-success story that is waiting for next steps" 72 : 1260-1266, 2018

39 Defronzo RA, "Prevention of diabetes with pioglitazone in ACT NOW : physiologic correlates" 62 : 3920-3926, 2013

40 Martono DP, "Predictors of response in initial users of metformin and sulphonylurea derivatives : a systematic review" 32 : 853-864, 2015

41 Inzucchi SE, "Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease" 39 : 1684-1692, 2016

42 Mannino GC, "Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine" 35 : e3109-, 2019

43 Kleinberger JW, "Personalized medicine in diabetes mellitus : current opportunities and future prospects" 1346 : 45-56, 2015

44 DeFronzo RA, "Pathophysiologic approach to therapy in patients with newly diagnosed type 2diabetes" 36 (36): S127-S138, 2013

45 Egan AG, "Pancreatic safety of incretin-based drugs : FDA and EMA assessment" 370 : 794-797, 2014

46 Chan J, "OP-0279Screening values of glycated haemoglobin suggest regional barriers in detecting T2DM early: analysis of the VERIFY study. IDF World Diabetes Congress"

47 Bouchoucha M, "Metformin and digestive disorders" 37 : 90-96, 2011

48 Hundal RS, "Mechanism by which metformin reduces glucose production in type 2 diabetes" 49 : 2063-2069, 2000

49 Davies MJ, "Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)" 41 : 2669-2701, 2018

50 Retnakaran R, "Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes : the LIBRA trial" 37 : 3270-3278, 2014

51 Jensen TM, "Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials" 38 : 1058-1066, 2015

52 UK Prospective Diabetes Study(UKPDS)Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)" 352 : 837-853, 1998

53 Pantalone KM, "Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large integrated health system" 39 : 1527-1534, 2016

54 Rosenstock J, "Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes" 8 : 650-660, 2006

55 Pfutzner A, "Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks" 13 : 567-576, 2011

56 Abdul-Ghani MA, "Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes(EDICT) : a randomized trial" 17 : 268-275, 2015

57 Rosenstock J, "Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes" 33 : 2406-2408, 2010

58 Haak T, "Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes : a randomized, double-blind, placebo-controlled study" 14 : 565-574, 2012

59 Lewin A, "Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes" 38 : 394-402, 2015

60 Thomsen RW, "Incretin-based therapy and risk of acute pancreatitis : a nationwide population-based case-control study" 38 : 1089-1098, 2015

61 Saisho Y, "Incretin-based therapy and pancreatitis : accumulating evidence and unresolved questions" 6 : 131-, 2018

62 Drucker DJ, "Incretin action in the pancreas : potential promise, possible perils, and pathological pitfalls" 62 : 3316-3323, 2013

63 Del Prato S, "Improving glucose management : ten steps to get more patients with type 2 diabetes to glycaemic goal" 59 : 1345-1355, 2005

64 Dimas AS, "Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity" 63 : 2158-2171, 2014

65 Leibowitz G, "Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53study" 17 : 487-494, 2015

66 Griffin SJ, "Impact of metformin on cardiovascular disease : a meta-analysis of randomised trials among people with type 2 diabetes" 60 : 1620-1629, 2017

67 RISE Consortium, "Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes" 41 : 1717-1725, 2018

68 Zoungas S, "Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes" 57 : 2465-2474, 2014

69 Monami M, "Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies" 53 : 35-40, 2016

70 International Diabetes Federation, "IDF diabetes atlas. 9th ed"

71 Levin PA, "Health outcomes associated with initiation of basal insulin after 1, 2, or ≥3 oral antidiabetes drug(s)among managed care patients with type 2 diabetes" 21 : 1172-1181, 2015

72 Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy" 355 : 2427-2443, 2006

73 Nalysnyk L, "Glycaemic variability and complications in patients with diabetes mellitus : evidence from a systematic review of the literature" 12 : 288-298, 2010

74 Matthews DR, "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes(VERIFY) : a 5-year, multicentre, randomised, double-blind trial" 394 : 1519-1529, 2019

75 Rosenstock J, "Euglycemic diabetic ketoacidosis : a predictable, detectable, and preventable safety concern with SGLT2 inhibitors" 38 : 1638-1642, 2015

76 Yoon KH, "Epidemic obesity and type 2 diabetes in Asia" 368 : 1681-1688, 2006

77 Yasuda N, "Enhanced secretion of glucagon-like peptide 1 by biguanide compounds" 298 : 779-784, 2002

78 Al Jobori H, "Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus" 103 : 1402-1407, 2018

79 Philis-Tsimikas A, "Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes : an open-label extension of the DURATION-1 study" 33 : 223-230, 2019

80 Williams-Herman D, "Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes" 12 : 442-451, 2010

81 Perez A, "Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM" 25 : 2915-2923, 2009

82 Yoon KH, "Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes : a 54-week study" 14 : 745-752, 2012

83 Cai X, "Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients : a systematic review and meta-analysis" 9 : 1995-2014, 2018

84 Wu D, "Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus : a meta-analysis" 16 : 30-37, 2014

85 Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes" 358 : 2545-2559, 2008

86 Bunck MC, "Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes" 34 : 2041-2047, 2011

87 Liu J, "Effects of SGLT2inhibitors on UTIs and genital infections in type 2 diabetes mellitus : a systematic review and meta-analysis" 7 : 2824-, 2017

88 Rosenstock J, "Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes : the CAROLINA randomized clinical trial" 322 : 1155-1166, 2019

89 UK Prospective Diabetes Study(UKPDS)Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" 352 : 854-865, 1998

90 Strain WD, "Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications" 166 : 108310-, 2020

91 Phung OJ, "Early combination therapy for the treatment of type 2 diabetes mellitus : systematic review and meta-analysis" 16 : 410-417, 2014

92 Lin J, "Does clinical inertia vary by personalized A1C goal? A study of predictors and prevalence of clinical inertia in a U. S. managedcare setting" 22 : 151-161, 2016

93 Schernthaner G, "Do we still need pioglitazone for the treatment of type 2 diabetes? A riskbenefit critique in 2013" 36 (36): S155-S161, 2013

94 Dunning BE, "Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetes" 49 (49): 110-111, 2006

95 Chan JC, "Diabetes in Asia : epidemiology, risk factors, and pathophysiology" 301 : 2129-2140, 2009

96 Khan M, "Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus" 2015 : 162718-, 2015

97 Paul SK, "Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes" 14 : 100-, 2015

98 Merovci A, "Dapagliflozin lowers plasma glucose concentration and improves β-cell function" 100 : 1927-1932, 2015

99 Ahren B, "DPP-4 inhibition and islet function" 3 : 3-10, 2012

100 de Pablos-Velasco P, "Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study" 80 : 47-56, 2014

101 Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm : 2017 executive summary" 23 : 207-238, 2017

102 American Association of Clinical Endocrinologists, "Comprehensive type 2 diabetes management algorithm (2019) executive summary"

103 DeFronzo RA, "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin" 38 : 384-393, 2015

104 Schnell O, "Clinical utility of SMBG : recommendations on the use and reporting of SMBG in clinical research" 38 : 1627-1633, 2015

105 Mathieu C, "Clinical safety and tolerability of vildagliptin : insights from randomised trials, observational studies and post-marketing surveillance" 13 : 68-72, 2017

106 Khunti K, "Clinical inertia in people with type 2 diabetes : a retrospective cohort study of more than 80, 000 people" 36 : 3411-3417, 2013

107 Strain WD, "Clinical inertia in individualising care for diabetes : is there time to do more in type 2 diabetes" 5 : 347-354, 2014

108 Reach G, "Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus" 43 : 501-511, 2017

109 Zhou K, "Clinical and genetic determinants of progression of type 2 diabetes : a DIRECT study" 37 : 718-724, 2014

110 Levin P, "Clinical and economic outcomes associated with the timing of initiation of basal insulin in patients with type 2 diabetes mellitus previously treated with oral antidiabetes drugs" 38 : 110-121, 2016

111 Kluger AY, "Class effects of SGLT2 inhibitors on cardiorenal outcomes" 18 : 99-, 2019

112 Abdelmoneim AS, "Cardiovascular safety of sulphonylureas : over 40years of continuous controversy without an answer" 17 : 523-532, 2015

113 Gastaldelli A, "Beta-cell dysfunction and glucose intolerance : results from the San Antonio metabolism(SAM)study" 47 : 31-39, 2004

114 Foley JE, "Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naïve patients with type 2diabetes and mild hyperglycaemia : a randomised controlled trial" 54 : 1985-1991, 2011

115 Matthews DR, "Baseline characteristics in the VERIFY study : a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed type 2 diabetes" 36 : 505-513, 2019

116 ORIGIN Trial Investigators, "Basal insulin and cardiovascular and other outcomes in dysglycemia" 367 : 319-328, 2012

117 Kunt T, "Barriers to insulin initiation and intensification and how to overcome them" 164 : 6-10, 2009

118 Defronzo RA, "Banting lecture. From the triumvirate to the ominous octet : a new paradigm for the treatment of type 2 diabetes mellitus" 58 : 773-795, 2009

119 Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35) : prospective observational study" 321 : 405-412, 2000

120 American Diabetes Association, "Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes : 2015" 38 (38): S41-S48, 2015

121 Takahara M, "Ameliorated pancreatic β cell dysfunction in type 2diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin" 62 : 77-86, 2015

122 American Association of Clinical Endocrinologists, "AACE/ACE clinical practice guidelines for developing a diabetes mellitus comprehensive care plan 2015"

123 Matthews DR, "A pre-specified statistical analysis plan for the VERIFY study : vildagliptin efficacy in combination with metformin for early treatment of T2DM" 21 : 2240-2247, 2019

124 Buse JB, "2019 Update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)" 63 : 221-228, 2020

125 Cosentino F, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD" 41 : 255-323, 2020

126 Holman RR, "10-Year follow-up of intensive glucose control in type 2 diabetes" 359 : 1577-1589, 2008